Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: Cancer Causes Control. 2015 Sep 16;26(12):1737–1750. doi: 10.1007/s10552-015-0667-4

Table 3.

Univariate multinomial logistic regression analyses of the associations between sociodemographic, reproductive, clinical, and tumor characteristics, and breast cancer subtype

Characteristic Luminal B (n = 70) Non-luminal HER2-expressing (n = 38) Triple-negative breast cancer (n = 91)

OR (95% CI)a OR (95% CI)a OR (95% CI)a
Sociodemographic characteristics
Age at diagnosis (years)
 <45 2.1 (1.2, 3.8) 1.9 (0.9, 4.1) 1.7 (1.0, 2.9)
 ≥45 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
Race
 White 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
 African American 1.9 (1.1, 3.1) 1.3 (0.7, 2.5) 2.7 (1.7, 4.3)
Marital statusb
 Married or living as married 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
 Unmarried 1.0 (0.6, 1.8) 1.8 (0.9, 3.7) 1.1 (0.6, 1.8)
 Unknown 0.8 (0.4, 1.6) 0.7 (0.2, 2.0) 1.0 (0.5, 1.8)
Education
 Below college 0.7 (0.4, 1.1) 1.1 (0.5, 2.2) 1.6 (1.0, 2.7)
 College graduate and above 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
 Unknown 0.3 (0.1, 0.9) 0.4 (0.1, 1.7) 1.6 (0.8, 3.3)
Annual household incomec
 <$70,000 1.2 (0.7, 2.3) 1.5 (0.7, 3.2) 1.8 (1.1, 3.2)
 ≥$70,000 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
 Unknown 1.0 (0.5, 1.9) 0.9 (0.4, 2.2) 1.2 (0.7, 2.3)
Primary health insurance
 Non-private 0.4 (0.2, 0.8) 0.7 (0.3, 1.5) 0.9 (0.5, 1.5)
 Private 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
 Unknown 1.0 (0.4, 2.7) 0.4 (0.1, 2.9) 1.1 (0.4, 2.7)
Reproductive and clinical characteristics
Menopausal status
 Pre 1.9 (1.1, 3.1) 1.2 (0.6, 2.5) 1.3 (0.8, 2.1)
 Post 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
Age at menarche (years)
 <12 0.6 (0.3, 1.5) 1.4 (0.5, 4.3) 1.6 (0.7, 3.6)
 12 – 13 1.1 (0.5, 2.1) 1.5 (0.5, 4.1) 1.6 (0.8, 3.4)
 >13 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
 Unknown 0.7 (0.3, 1.5) 0.8 (0.2, 2.8) 1.4 (0.6, 3.2)
Parity
 Nulliparous 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
 Parous 1.2 (0.6, 2.4) 1.0 (0.4, 2.4) 1.0 (0.5, 1.9)
 Unknown 0.8 (0.3, 1.8) 0.6 (0.2, 1.9) 1.0 (0.5, 2.0)
Parityd
 1 – 2 children 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
 ≥3 children 0.9 (0.4, 1.6) 0.9 (0.4, 2.2) 1.0 (0.6, 1.9)
History of breastfeedingd
 No 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
 Yes 1.1 (0.6, 2.1) 1.2 (0.5, 2.6) 0.7 (0.4, 1.3)
History of oral contraceptive use
 Never 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
 Ever 1.1 (0.6, 2.0) 1.0 (0.5, 2.2) 1.3 (0.8, 2.4)
 Unknown 0.7 (0.3, 1.6) 0.6 (0.2, 1.7) 1.2 (0.6, 2.3)
History of HRT use
 Never 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
 Ever 0.7 (0.3, 1.5) 1.1 (0.4, 2.6) 1.1 (0.6, 2.1)
 Unknown 0.6 (0.3, 1.2) 0.6 (0.2, 1.5) 1.0 (0.6, 1.7)
Family history of breast cancer
 No 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
 Yes 1.0 (0.6, 1.6) 0.6 (0.3, 1.3) 0.8 (0.5, 1.3)
BMI (kg/m2)
 <25.0 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
 25.0 – 29.99 0.9 (0.5, 1.7) 1.0 (0.5, 2.3) 1.7 (0.9, 3.1)
 ≥30.0 0.9 (0.5, 1.6) 0.6 (0.3, 1.3) 1.4 (0.8, 2.4)
 Unknown
Comorbid conditions
 0 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
 ≥1 0.6 (0.3, 1.0) 0.8 (0.4, 1.6) 1.1 (0.6, 2.0)
Diabetes
 Yes 1.4 (0.7, 2.7) 1.9 (0.8, 4.5) 1.1 (0.6, 2.2)
 No 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
Hypertension
 Yes 1.0 (0.6, 1.6) 0.8 (0.4, 1.6) 1.4 (0.9, 2.2)
 No 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
Osteoporosis/osteopenia
 Yes 0.6 (0.3, 1.1) 0.5 (0.2, 1.2) 0.6 (0.4, 1.1)
 No 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
Arthritis
 Yes 0.8 (0.5, 1.6) 1.1 (0.5, 2.4) 0.6 (0.3, 1.1)
 No 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
Tumor characteristics
Mode of detection
 Patient self-detecting 1.8 (1.1, 3.1) 2.4 (1.2, 4.7) 2.7 (1.7, 4.2)
 Patient not self-detecting 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
History of benign breast disease
 No 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
 Yes 0.8 (0.5, 1.3) 1.1 (0.6, 2.2) 0.6 (0.4, 1.0)
Tumor grade
 Well/moderately differentiated 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
 Poorly differentiated 3.3 (1.9, 5.6) 16.7 (6.7, 41.5) 13.8 (7.9, 24.4)
 Unknown -- -- --
AJCC stage
 Stage I 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
 Stage II and above 1.9 (1.1, 3.2) 2.6 (1.3, 5.2) 1.8 (1.2, 2.9)
 Unknown -- -- --
Tumor size (cm)
 ≤1.0 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
 >1.0 2.0 (1.1, 3.5) 2.5 (1.1, 5.7) 3.4 (1.9, 6.2)
Lymph node status
 Negative 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
 Positive 1.3 (0.8, 2.3) 1.1 (0.5, 2.3) 1.2 (0.7, 2.0)
 Unknown -- -- --
Lymphovascular invasion present
 No 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
 Yes 1.9 (1.1, 3.4) 0.9 (0.4, 2.4) 1.2 (0.7, 2.1)
 Unknown 0.9 (0.3, 2.1) 1.7 (0.7, 4.2) 1.3 (0.7, 2.6)
p53 status positive
 No 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
 Yes 2.1 (0.7, 6.1) 3.3 (1.0, 10.4) 5.0 (2.3, 10.8)
Ki67 status positive
 No 1.0 (Referent) 1.0 (Referent) 1.0 (Referent)
 Yes 2.6 (1.5, 4.5) 2.7 (1.3, 5.5) 4.2 (2.6, 6.7)

Abbreviations: HER2, human epidermal growth factor receptor 2; OR, odds ratio; CI, confidence interval; BMI, body mass index; HRT, Hormone Replacement Therapy; AJCC, American Joint Committee on Cancer.

a

ORs and 95% CIs were generated from univariate multinomial logistic regression models with the luminal A subtype as the referent group.

b

The unmarried group was composed of those who were single/never been married, separated, divorced, or widowed.

c

$70,000 is the median income among households in New Jersey and thus was used as the cut-point to dichotomize the income variable.

d

Number of children and history of breastfeeding were among parous women only (N = 385).